SLC7A11 and head and neck cancer: The FDA-approved class I FIN sulfasalazine (SAS) has been shown to induce cell ferroptosis in breast and head and neck cancers by inhibiting SLC7A11, as evidenced by studies (Kim et al., 2018; Yu H. et al., 2019).